The post Hugging Face co-founder doubts AI’s scientific abilities appeared on BitcoinEthereumNews.com. People are inclined to pay attention when the co-founder of Hugging Face, a $4.5 billion artificial intelligence start-up, shares his thoughts on the direction of science. Thomas Wolf, however, does not agree with the evangelists. Rather, he has raised questions about whether the AI systems being developed today would bring about the significant scientific advancements that some of their proponents prefer to think about. The Hugging Face guru explains why chatbots are not perfect The comments made him to go against other AI industry prominent figures, with Dario Amodei of Anthropic and Sam Altman of OpenAI say notable and significant change is closer than before. In a blog, Amodei suggested that AI has the possibility to compress centuries of biological data into a 10-year study. Wolf is not convinced that AI will be significant and according to him, scientific breakthroughs must be the kind of innovations that make our understanding of the world much easier. He argues that AI models of today are not at par with Copernicus who suggested that the sun and not the earth was the centre of the solar system. Wolf clarified the two issues, starting with ChatGPT and similar systems that tend to align with the person using them. “When you ask a question, the AI you are using hypes you through describing it as interesting or important, and this kind of hyping as much as it is good, does not usually lead to scientific thought revolution.” Wolf. Secondly, the next word in a sequence is what these massive language models are being trained to guess and anticipate and they intentionally produce predicted results rather than the unexpected ones. On the other hand, serious paradigm shift scientists seldom choose the easiest route. “The scientist is not trying to predict the most likely next word. He’s… The post Hugging Face co-founder doubts AI’s scientific abilities appeared on BitcoinEthereumNews.com. People are inclined to pay attention when the co-founder of Hugging Face, a $4.5 billion artificial intelligence start-up, shares his thoughts on the direction of science. Thomas Wolf, however, does not agree with the evangelists. Rather, he has raised questions about whether the AI systems being developed today would bring about the significant scientific advancements that some of their proponents prefer to think about. The Hugging Face guru explains why chatbots are not perfect The comments made him to go against other AI industry prominent figures, with Dario Amodei of Anthropic and Sam Altman of OpenAI say notable and significant change is closer than before. In a blog, Amodei suggested that AI has the possibility to compress centuries of biological data into a 10-year study. Wolf is not convinced that AI will be significant and according to him, scientific breakthroughs must be the kind of innovations that make our understanding of the world much easier. He argues that AI models of today are not at par with Copernicus who suggested that the sun and not the earth was the centre of the solar system. Wolf clarified the two issues, starting with ChatGPT and similar systems that tend to align with the person using them. “When you ask a question, the AI you are using hypes you through describing it as interesting or important, and this kind of hyping as much as it is good, does not usually lead to scientific thought revolution.” Wolf. Secondly, the next word in a sequence is what these massive language models are being trained to guess and anticipate and they intentionally produce predicted results rather than the unexpected ones. On the other hand, serious paradigm shift scientists seldom choose the easiest route. “The scientist is not trying to predict the most likely next word. He’s…

Hugging Face co-founder doubts AI’s scientific abilities

For feedback or concerns regarding this content, please contact us at crypto.news@mexc.com

People are inclined to pay attention when the co-founder of Hugging Face, a $4.5 billion artificial intelligence start-up, shares his thoughts on the direction of science. Thomas Wolf, however, does not agree with the evangelists.

Rather, he has raised questions about whether the AI systems being developed today would bring about the significant scientific advancements that some of their proponents prefer to think about.

The Hugging Face guru explains why chatbots are not perfect

The comments made him to go against other AI industry prominent figures, with Dario Amodei of Anthropic and Sam Altman of OpenAI say notable and significant change is closer than before. In a blog, Amodei suggested that AI has the possibility to compress centuries of biological data into a 10-year study.

Wolf is not convinced that AI will be significant and according to him, scientific breakthroughs must be the kind of innovations that make our understanding of the world much easier. He argues that AI models of today are not at par with Copernicus who suggested that the sun and not the earth was the centre of the solar system.

Wolf clarified the two issues, starting with ChatGPT and similar systems that tend to align with the person using them.

Secondly, the next word in a sequence is what these massive language models are being trained to guess and anticipate and they intentionally produce predicted results rather than the unexpected ones.

On the other hand, serious paradigm shift scientists seldom choose the easiest route. “The scientist is not trying to predict the most likely next word. He’s trying to predict this very novel thing that’s actually surprisingly unlikely, but actually is true,” Wolf said.

The Hugging Face co-founder has been thinking about this topic for the last few months. His interest was sparked after he read an essay penned by Anthropic’s Amodei, who posited that “AI-enabled biology and medicine will allow us to compress the progress that human biologists would have achieved over the next 50-100 years into 5-10 years.”

Startups are pursuing their goals

Wolf acknowledges that he has been thinking about the topic for months and he grew less convinced the more he flipped Amodei’s forecasts around in his mind. He sees a more humble reality, where AI might be a supporting tool rather than a game-changer.

AlphaFold, an AI system developed by Google’s DeepMind that mapped protein structures and created new avenues for drug discovery, caused a stir.

According to Wolf, AI is just a support acts even though it is super advanced, and they facilitate speedier material navigation, but they cannot replace the bizarre creative leaps that define Nobel-caliber discoveries.

All this talk by Wolf has not discouraged new businesses from entering the stage, and some organizations such as FutureHouse and Lila Sciences have promised to apply AI in their innovation processes. However, it remains an observatory period of how many will fulfill those promises.

The negative thoughts and opinions by Wolf are a good counterbalance to those who only shoot positive predictions in the industry.

According to him, AI has the capacity to revolutionize laboratory work and spur small steps forward, but when it comes to rewriting the rules of knowledge itself, he believes the burden still rests on human shoulders.

A recent article by Cryptopolitan also shows how Silicon Valley also strongly believes that AI can help humans with the gift of near immortality, making humans live up to 200 years.

Claim your free seat in an exclusive crypto trading community – limited to 1,000 members.

Source: https://www.cryptopolitan.com/hugging-face-co-founder-doubts-ais-abilities/

Market Opportunity
null Logo
null Price(null)
--
----
USD
null (null) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact crypto.news@mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Vitalik Buterin to Ethereum Developers: Build It Like It Has to Last Without You

Vitalik Buterin to Ethereum Developers: Build It Like It Has to Last Without You

Key Takeaways Vitalik Buterin wants Ethereum apps built to survive without developers, corporate servers, or trusted third parties Two major […] The post Vitalik
Share
Coindoo2026/03/07 15:49
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26
Short-term profit-taking pushes Bitcoin back below key $70K level – What next?

Short-term profit-taking pushes Bitcoin back below key $70K level – What next?

The post Short-term profit-taking pushes Bitcoin back below key $70K level – What next? appeared on BitcoinEthereumNews.com. Bitcoin [BTC] rallied as high as $74
Share
BitcoinEthereumNews2026/03/07 16:09